CD32-dependent platelet activation by a drug-dependent antibody to glycoprotein IIb/IIIa antagonists

Thrombosis and Haemostasis

Volumn 89, Issue 3, 2003, Pages 513-521

  Pedicord, Donna L ^a   Dicker, Ira ^a   O'Neil, Karyn ^a,b   Breth, Leah ^a   Wynn, Richard ^a,c   Hollis, Greogory F ^a,c   Billheimer, Jeffrey T ^a   Stern, Andrew M ^a   Seiffert, Dietmar ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b CENTOCOR INC   (United States)

^c Experimental Station   (United States)

Author keywords

Platelets drug dependent antibodies glycoprotein IIb IIIa thrombocytopenia

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CALCIMYCIN; CD32 ANTIGEN; CHROMOGENIC SUBSTRATE; CYCLIC AMP; DEXTRO PHENYLALANYLPIPECOLYLARGININE 4 NITROANILIDE; FIBRINOGEN RECEPTOR ANTAGONIST; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY JK 96; NEUTRALIZING ANTIBODY; PHOSPHOLIPID; ROXIFIBAN; UNCLASSIFIED DRUG;

ANTIBODY COMBINING SITE; ANTICOAGULATION; ARTICLE; CELL ASSAY; CELL STIMULATION; CONTROLLED STUDY; DRUG EXPOSURE; DRUG MECHANISM; DRUG RECEPTOR BINDING; ENZYME INHIBITION; HUMAN; HUMAN CELL; INCUBATION TIME; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE METABOLISM; THROMBOCYTOPENIA;

EID: 0037338953     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613382     Document Type: Article

References (39)

1. Cannon CP. The evolving story of oral platelet glycoprotein IIb/IIIa receptor inhibitors. Current Opinion in Cardiovascular, Pulmonary & Renal Investigational Drugs 2000; 2: 114-23.
2. Nurden AT, Poujol C, Durrieu-Jais C, Nurden P. Platelet glycoprotein IIb/IIIa inhibitors: Basic and Clinical Aspects. Arterioscler Thromb Vasc Biol 1999; 19: 2835-40.
3. The Prism Plus Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. New England J Med 1998; 338: 1488-97.
4. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibratide in patients with acute coronary syndromes. New Engl J Med 1998; 339: 436-43.
5. The EPIC Investigators 1994. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa recpetor in high risk angioplasty. New Engl J Med 330: 956-61.
6. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. New Engl J Med 1997; 336: 1689-96.
7. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997; 349: 1429-35.
8. The EPISTENT Investigators. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess the safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockage. Lancet 1998; 352: 87-92.
9. Billheimer JT, Dicker IB, Wynn R, Bradley JD, Cromley DA, Godonis HE, Grimminger LC, He B, Kieras CJ, Pedicord DL, et al. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood 2002; 99: 3540-6.
10. Seiffert D, Stern AM, Ebling W, Rossi RJ, Barrett YC, Wynn R, Hollis GF, He B, Kieras CJ, Pedicord DL, et al. Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: Implications for the etiology of thrombocytopenia. Blood 2002; 101: 58-63.
11. Shulman NR, Reid DM. Platelet immunology. In: Hemostasis and Thrombosis. Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Philadelphia: Lippincott 1994; 414-68.
12. Kelton JG. The serological investigation of patients with autoimmune thrombocytopenia. Thromb Haemost 1995; 74: 228-33.
13. Chong BH. Drug-induced immune thrombocytopenia. Platelets 1991; 2: 173-81.
14. Hackett T, Kelton JG, Powers P. Drug-induced platelet destruction. Semin Thromb Hemost 1982; 8: 116-37.
15. Patton WN, Duffull SB. Idiosyncratic drug-induced haematological abnormalities. Pharmacoepidemiology 1994; 11: 445-62.
16. Aster RH. Drug-induced immune thrombocytopenia: An overview of pathogenesis. Semin Hematol 1999; 36: 2-6.
17. Salzman EW, Hirsh J, Marder VJ. Clinical use of heparin. In: Hemostasis and Thrombosis. Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Philadelphia: Lippincott. 1994; 1584-91.
18. Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: Towards Consensus. Thromb Haemost 1998; 79: 1-7.
19. Kunicki TJ. Platelet immunology. In: Hemostasis and Thrombosis. Coleman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Philadelphia: Lippincott Williams & Wilkins. 2000: 461-77.
20. George JN. Platelet kinetics and pathophysiology of thrombocytopenia. In: Hemostasis and Thrombosis. Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Philadelphia: Lippincott Williams & Wilkins. 2000: 447-59.
21. Zolotarjova NI, Hollis GF, Wynn R. Unusually stable and long-lived ligand-induced conformations of integrins. J Biol Chem 2001; 276: 17063-8.
22. Frelinger AL, Cohen I, Plow EF, Smith MA, Roberts J, Lam SC, Ginsberg MH. Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J Biol Chem 1990; 265: 6346-52.
23. Frelinger AL, Du XP, Plow EF, Ginsberg MH. Monoclonal antibodies to ligand-occupied conformers of integrin alpha Ib beta 3 (glycoprotein IIb/IIIa) alter receptor affinity, specificity, and function. J Biol Chem 1991; 266: 17106-11.
24. Kouns WC, Kirchhofer D, Hadvary P, Edenhofer A, Weller T, Pfenninger G, Baumgartner HR, Jennings LK, Steiner B. Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidometic inhibitor. Blood 1992; 80: 2539-47.
25. Mondoro TH, Wall CD, White MM, Jennings LK. Selective induction of a glycoprotein IIIa ligand-induced binding site by fibrinogen and von Willebrand factor. Blood 1996; 88: 3824-30.
26. Mazurov AV, Khaspekova SG, Byzova TV, Tikhomirov OY, Berndt MC, Steiner B, Kouns WC. Stimulation of platelet glycoprotein IIb-IIIa (alpha IIb beta 3-integrin) functional activity by a monoclonal antibody to the N-terminal region of glycoprotein IIIa. FEBS Lett 1996; 391: 84-88.
27. Hillman M, Zolotarjova NI, Patrick D, McCabe D, Shen K, Corman J, Billheimer JT, Seiffert D, Hollis GF. Large-scale purification of active platelet integrin glycoprotein IIb/IIIa. Protein Expr Purif 2002; 25: 494-502.
28. Pedicord DL, Thomas BE, Mousa SA, Dicker IB. Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity. Thromb Res 1998; 90: 247-58.
29. Dekkers DW, Comfurius P, Vuist WM, Billheimer JT, Dicker I, Weiss HJ, Zwaal RF, Bevers EM Impaired calcium-induced tyrosine phosphorylation and defective lipid scrambling in erythrocytes from a patient with Scott's syndrome: A study using an inhibitor for scramblase that mimics the defect in Scott syndrome. Blood 1998; 91: 2133-8.
30. Kouns WC, Wall CD, White MM, Fox CF, Jennings LK. A conformation-dependent epitope of human glycoprotein IIIa. J Biol Chem 1990; 265: 20594-601.
31. Gulino D, Ryckewaert JJ, Andrieuz A, Rabiet MJ, Marguerie G. Identification of a monoclonal antibody against platelet GP IIb that interacts with a calcium-binding site and induces aggregation. J Biol Chem 1990; 265: 9575-81.
32. Kouns WC, Jennings LK. Activation-independent exposure of the GP IIb/IIIa fibrinogen receptor. Thromb Res 1991; 63: 343-54.
33. Modderman PW, Huisman HG, Mourik J, Von Dem Borne AEGK. A monoclonal antibody to the human platelet glycoprotein IIb/IIIa complex induces platelet activation. Thromb Haemost 1988; 60: 68-74.
34. Hornby EJ, Brown S, Wilkinson JM, Mattock C, Authi KS. Activation of human platelets by exposure to a monoclonal antibody, PM6/248, to glycoprotein IIb/IIIa. Br J Haematol 1991; 79: 277-85.
35. Bachelot C, Rendu F, Boucheix C, Hogg N, Levy-Toledano S. Activation of platelets induced by mAb P256 specific for glycoprotein IIb/IIIa. Eur J Biochem 1990; 190: 177-83.
36. Bevers EM, Comfurius P, Reutelingsperger CPM, Zwaal RFA. Platelet procoagulant activity and its measurement. In: Platelets, a Practical Approach. Watson SP, Authi KS, eds. Oxford: IRL Press 1996: 319-40.
37. Schick PK. Platelet and megakaryocyte lipids. In: Hemostasis and Thrombosis. Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Philadelphia: Lippincott Williams & Wilkins 2000; 522-532.
38. Tracy PB. Role of platelets and leukocytes in coagulation. In: Hemostasis and Thrombosis. Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Philadelphia: Lippincott Williams & Wilkins 2000: 575-96.
39. Wilkinson JM. Monoclonal antibodies to platelet cell surface antigens and their use. In: Platelets, a Practical Approach. Watson SP, Authi KS, eds. Oxford: IRL Press. 1996; 155-72.